A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

NCT06890832 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer, MCRPC

Interventions

DRUG: 50 mg cabazitaxel
DRUG: 100 mg cabazitaxel
DRUG: 200 mg cabazitaxel

Sponsor

Jina Pharmaceuticals Inc.